Skip to main content

Table 3 Severity of symptoms at baseline, during 16 weeks’ treatment and after one month’s follow-up)

From: A randomized placebo-controlled clinical trial of a multi-strain probiotic formulation (Bio-Kult®) in the management of diarrhea-predominant irritable bowel syndrome

Severity of IBS-D Probiotic (Bio-Kult®) (n = 181) Placebo (n = 179) P-value
Baseline
 Moderate 39 (21.5) 52 (29.1) 0.101
 Severe 142 (78.5) 127 (70.9)
Month 1
 Symptoms free period 2 (1.1) 2 (1.1) 0.086
 Mild 78 (43.1) 58 (32.4)
 Moderate 91 (50.3) 99 (55.3)
 Severe 10 (5.5) 20 (11.2)
Month 2
 Symptoms free period 16 (8.8) 18 (10.1) < 0.001
 Mild 112 (61.9) 61 (34.1)
 Moderate 42 (23.2) 82 (45.8)
 Severe 11 (6.1) 18 (10.1)
Month 3
 Symptoms free period 54 (29.8) 20 (11.2) < 0.001
 Mild 98 (54.1) 62 (34.6)
 Moderate 23 (12.7) 57 (31.8)
 Severe 6 (3.3) 40 (22.3)
Month 4
 Symptoms free period 56 (30.4) 22 (11.2) < 0.001
 Mild 99 (54.7) 68 (38.0)
 Moderate 21 (11.6) 66 (36.9)
 Severe 6 (3.3) 23 (12.8)
Follow-up: Month 5
 Symptoms free period 61 (33.7) 23 (12.8) < 0.001
 Mild 95 (52.5) 70 (39.1)
 Moderate 21 (11.6) 65 (36.3)
 Severe 4 (2.2) 21 (11.7)
  1. The unpaired Chi-square test was used to determine the level of statistical significance